Research Analysts Offer Predictions for TMDX FY2024 Earnings

TransMedics Group, Inc. (NASDAQ:TMDX) – Equities researchers at William Blair cut their FY2024 earnings estimates for shares of TransMedics Group in a research note issued to investors on Monday, December 2nd. William Blair analyst R. Daniels now anticipates that the company will post earnings of $1.04 per share for the year, down from their previous estimate of $1.06. The consensus estimate for TransMedics Group’s current full-year earnings is $1.01 per share. William Blair also issued estimates for TransMedics Group’s Q4 2024 earnings at $0.21 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.47 EPS, FY2025 earnings at $1.66 EPS, Q1 2026 earnings at $0.56 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.55 EPS and FY2026 earnings at $2.44 EPS.

Several other research analysts also recently weighed in on the stock. Piper Sandler cut their target price on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Oppenheimer reissued an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday. JPMorgan Chase & Co. lowered their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. TD Cowen lowered their price target on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Finally, Canaccord Genuity Group lowered their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $131.80.

TransMedics Group Trading Down 16.1 %

Shares of TMDX stock opened at $71.44 on Wednesday. The firm has a 50-day moving average price of $108.52 and a 200 day moving average price of $135.34. TransMedics Group has a twelve month low of $68.84 and a twelve month high of $177.37. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of 76.00 and a beta of 2.06. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.12) EPS.

Insider Transactions at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. This represents a 12.27 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This represents a 12.43 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,958 shares of company stock worth $3,470,328. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently made changes to their positions in TMDX. International Assets Investment Management LLC acquired a new stake in shares of TransMedics Group during the 2nd quarter valued at approximately $47,000. USA Financial Formulas acquired a new stake in TransMedics Group in the third quarter worth $55,000. Quarry LP increased its position in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after buying an additional 312 shares during the period. National Bank of Canada FI increased its position in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after buying an additional 262 shares during the period. Finally, J.Safra Asset Management Corp increased its position in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after buying an additional 383 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.